Tag: oophorectomy

Articles

• BRCA1 and BRCA2 mutation carriers

Studies

• Risk of endometrial cancer after RRSO in BRCA 1/2 carriers: a multicentre cohort study Cite
  Pla-Juher H, Pardo M, Izquierdo ÀJ, Darder E, Carbó A, Munté E, et al. Risk of endometrial cancer after RRSO in BRCA 1/2 carriers: a multicentre cohort study. Clinical and Translational Oncology. Springer Science and Business Media LLC; 2023; 26:1033-1037 10.1007/s12094-023-03312-4
• Bilateral Oophorectomy and All-Cause Mortality in Women With BRCA1 and BRCA2 Sequence Variations Cite
  Kotsopoulos J, Gronwald J, Huzarski T, Møller P, Pal T, McCuaig JM, et al. Bilateral Oophorectomy and All-Cause Mortality in Women With BRCA1 and BRCA2 Sequence Variations. JAMA Oncology. American Medical Association (AMA); 2024; 10.1001/jamaoncol.2023.6937
• Suboptimal use of ovarian function suppression in very young women with early breast cancer: a real-world data study Cite
  Heredia A, Walbaum B, Vidal M, Itriago L, Camus M, Dominguez F, et al. Suboptimal use of ovarian function suppression in very young women with early breast cancer: a real-world data study. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2023; 10.1007/s10549-023-07117-5
• Clinical significance of risk-reducing salpingo-oophorectomy in patients with BRCA1/2 mutation Cite
  Tuna M, Özgen L, Yalcin Y, Ozerkan K. Clinical significance of risk-reducing salpingo-oophorectomy in patients with BRCA1/2 mutation. Journal of Gynecology Obstetrics and Human Reproduction. Elsevier BV; 2023;:102642 10.1016/j.jogoh.2023.102642
• Abstract 988: Long-term health outcomes of bilateral salpingo-oophorectomy in women with personal history of breast cancer Cite
  Hassan H, Rahman T, Bacon A, Knott C, Allen I, Huntley C, et al. Abstract 988: Long-term health outcomes of bilateral salpingo-oophorectomy in women with personal history of breast cancer. Cancer Research. American Association for Cancer Research (AACR); 2023; 83:988-988 10.1158/1538-7445.am2023-988
• Association of Premenopausal Bilateral Oophorectomy With Parkinsonism and Parkinson Disease Cite
  Rocca WA, Smith CY, Gazzuola Rocca L, Savica R, Mielke MM. Association of Premenopausal Bilateral Oophorectomy With Parkinsonism and Parkinson Disease. JAMA Network Open. American Medical Association (AMA); 2022; 5:e2238663 10.1001/jamanetworkopen.2022.38663
• Risk-reducing salpingo-oophorectomy for Japanese women with hereditary breast and ovarian cancer: a single-institution 10-year experience Cite
  Nagashima M, Ishikawa T, Asami Y, Hirose Y, Shimada K, Miyagami S, et al. Risk-reducing salpingo-oophorectomy for Japanese women with hereditary breast and ovarian cancer: a single-institution 10-year experience. Japanese Journal of Clinical Oncology. Oxford University Press (OUP); 2023; 10.1093/jjco/hyad020
• Breast Cancer Risk and Breast-Cancer-Specific Mortality following Risk-Reducing Salpingo-Oophorectomy in BRCA Carriers: A Systematic Review and Meta-Analysis Cite
  Gaba F, Blyuss O, Tan A, Munblit D, Oxley S, Khan K, et al. Breast Cancer Risk and Breast-Cancer-Specific Mortality following Risk-Reducing Salpingo-Oophorectomy in BRCA Carriers: A Systematic Review and Meta-Analysis. Cancers. MDPI AG; 2023; 15:1625 10.3390/cancers15051625
• The risks of cancer in older women with BRCA pathogenic variants: How far have we come? Cite
  Metcalfe KA, Gronwald J, Tung NM, McCuaig JM, Eisen A, Elser C, et al. The risks of cancer in older women with BRCA pathogenic variants: How far have we come?. Cancer. Wiley; 2022; 129:901-907 10.1002/cncr.34615
• Hysterectomy, bilateral oophorectomy, and breast cancer risk in a racially diverse prospective cohort study Cite
  Lovett SM, Sandler DP, O’Brien KM. Hysterectomy, bilateral oophorectomy, and breast cancer risk in a racially diverse prospective cohort study. JNCI: Journal of the National Cancer Institute. Oxford University Press (OUP); 2023; 10.1093/jnci/djad038
• Risk-Reducing Breast and Gynecological Surgery for BRCA Mutation Carriers: A Narrative Review Cite
  Bertozzi S, Londero AP, Xholli A, Azioni G, Di Vora R, Paudice M, et al. Risk-Reducing Breast and Gynecological Surgery for BRCA Mutation Carriers: A Narrative Review. Journal of Clinical Medicine. MDPI AG; 2023; 12:1422 10.3390/jcm12041422
• Surgical management of BRCA-mutation carriers: A single institution experience Cite
  Gentile D, Losurdo A, Sagona A, Zuradelli M, Gatzemeier W, Barbieri E, et al. Surgical management of BRCA-mutation carriers: A single institution experience. European Journal of Surgical Oncology. Elsevier BV; 2022; 48:1706-1712 10.1016/j.ejso.2022.04.024
• Bilateral Oophorectomy and the Risk of Breast Cancer in BRCA1 Mutation Carriers: A Reappraisal Cite
  Kotsopoulos J, Lubinski J, Gronwald J, Menkiszak J, McCuaig J, Metcalfe K, et al. Bilateral Oophorectomy and the Risk of Breast Cancer in BRCA1 Mutation Carriers: A Reappraisal. Cancer Epidemiology, Biomarkers & Prevention. American Association for Cancer Research (AACR); 2022; 31:1351-1358 10.1158/1055-9965.epi-21-1196
• Genetic, clinic and histopathologic characterization of BRCA-associated hereditary breast and ovarian cancer in southwestern Finland Cite
  Pallonen TA, Lempiäinen SMM, Joutsiniemi TK, Aaltonen RI, Pohjola PE, Kankuri-Tammilehto MK. Genetic, clinic and histopathologic characterization of BRCA-associated hereditary breast and ovarian cancer in southwestern Finland. Scientific Reports. Springer Science and Business Media LLC; 2022; 12 10.1038/s41598-022-10519-y
• The impact of oophorectomy on survival from breast cancer in patients with CHEK2 mutations Cite
  Tomiczek-Szwiec J, Szwiec M, Falco M, Cybulski C, Wokolorczyk D, Jakubowska A, et al. The impact of oophorectomy on survival from breast cancer in patients with CHEK2 mutations. British Journal of Cancer. Springer Science and Business Media LLC; 2022; 10.1038/s41416-022-01770-1
• Risk-reducing salpingo-oophorectomy and breast cancer risk in BRCA1 or BRCA2 mutation carriers: A systematic review and meta-analysis Cite
  Wang Y, Song Z, Zhang S, Wang X, Li P. Risk-reducing salpingo-oophorectomy and breast cancer risk in BRCA1 or BRCA2 mutation carriers: A systematic review and meta-analysis. European Journal of Surgical Oncology. Elsevier BV; 2022; 10.1016/j.ejso.2022.02.019
• Bilateral Salpingo-oophorectomy and Breast Cancer Risk for BRCA1 and BRCA2 Mutation Carriers: Assessing the Evidence Cite
  Conduit C, Milne RL, Friedlander ML, Phillips K. Bilateral Salpingo-oophorectomy and Breast Cancer Risk for BRCA1 and BRCA2 Mutation Carriers: Assessing the Evidence. Cancer Prevention Research. American Association for Cancer Research (AACR); 2021; 14:983-994 10.1158/1940-6207.capr-21-0141
• Risk-Reducing Salpingo-oophorectomy (RRSO) Cite
  Kobayashi Y, Aoki D. Risk-Reducing Salpingo-oophorectomy (RRSO). Hereditary Breast and Ovarian Cancer. Springer Singapore; 2021;:183-191 10.1007/978-981-16-4521-1_12
• Breast cancer risk and hormone replacement therapy among BRCA carriers after risk-reducing salpingo-oophorectomy Cite
  Michaelson-Cohen R, Gabizon–Peretz S, Armon S, Srebnik-Moshe N, Mor P, Tomer A, et al. Breast cancer risk and hormone replacement therapy among BRCA carriers after risk-reducing salpingo-oophorectomy. European Journal of Cancer. Elsevier BV; 2021; 148:95-102 10.1016/j.ejca.2021.02.007
• Survival from breast cancer in women with a BRCA2 mutation by treatment Cite
  Evans DG, Phillips K, Milne RL, Fruscio R, Cybulski C, Gronwald J, et al. Survival from breast cancer in women with a BRCA2 mutation by treatment. British Journal of Cancer. Springer Science and Business Media LLC; 2021; 10.1038/s41416-020-01164-1
• Breast cancer survival in Nordic BRCA2 mutation carriers—unconventional association with oestrogen receptor status Cite
  Olafsdottir EJ, Borg A, Jensen M, Gerdes A, Johansson ALV, Barkardottir RB, et al. Breast cancer survival in Nordic BRCA2 mutation carriers—unconventional association with oestrogen receptor status. British Journal of Cancer. Springer Science and Business Media LLC; 2020; 123:1608-1615 10.1038/s41416-020-01056-4
• Predictors of long-term cancer-related distress among female BRCA1 and BRCA2 mutation carriers without a cancer diagnosis: an international analysis Cite
  Metcalfe KA, Price MA, Mansfield C, Hallett DC, Lindeman GJ, Fairchild A, et al. Predictors of long-term cancer-related distress among female BRCA1 and BRCA2 mutation carriers without a cancer diagnosis: an international analysis. British Journal of Cancer. Springer Science and Business Media LLC; 2020; 123:268-274 10.1038/s41416-020-0861-3
• Abstract C052: Premenopausal oophorectomy and survival among women with breast cancer: Evidence of effect measure modification by family history status Cite
  Roberson ML, Robinson WR, Nichols HB, Olshan AF, Troester MA. Abstract C052: Premenopausal oophorectomy and survival among women with breast cancer: Evidence of effect measure modification by family history status. Poster Presentations - Proffered Abstracts. American Association for Cancer Research; 2020; 10.1158/1538-7755.disp18-c052
• Association of premenopausal risk-reducing salpingo-oophorectomy with breast cancer risk in BRCA1/2 mutation carriers: Maximising bias-reduction Cite
  Stjepanovic N, Villacampa G, Nead KT, Torres-Esquius S, Melis GG, Nathanson KL, et al. Association of premenopausal risk-reducing salpingo-oophorectomy with breast cancer risk in BRCA1/2 mutation carriers: Maximising bias-reduction. European Journal of Cancer. Elsevier BV; 2020; 132:53-60 10.1016/j.ejca.2020.03.009
• Incidence and Risk Factors of Ovarian Cancer and Breast Cancer Following Prophylactic Surgery: A Retrospective Cohort Study Cite
  Rettenmaier MA, Micha JP, Bohart R, Epstein HD, King MM, Goldstein BH. Incidence and Risk Factors of Ovarian Cancer and Breast Cancer Following Prophylactic Surgery: A Retrospective Cohort Study. Journal of Gynecologic Surgery. Mary Ann Liebert Inc; 2020; 36:189-193 10.1089/gyn.2019.0135
• Risk-reducing salpingo-oophorectomy, natural menopause, and breast cancer risk: an international prospective cohort of BRCA1 and BRCA2 mutation carriers Cite
  Mavaddat N, Antoniou AC, Mooij TM, Hooning MJ, Heemskerk-Gerritsen BA, Noguès C, et al. Risk-reducing salpingo-oophorectomy, natural menopause, and breast cancer risk: an international prospective cohort of BRCA1 and BRCA2 mutation carriers. Breast Cancer Research. Springer Science and Business Media LLC; 2020; 22 10.1186/s13058-020-1247-4
• Oophorectomy and risk of contralateral breast cancer among BRCA1 and BRCA2 mutation carriers Cite
  Kotsopoulos J, Lubinski J, Lynch HT, Tung N, Armel S, Senter L, et al. Oophorectomy and risk of contralateral breast cancer among BRCA1 and BRCA2 mutation carriers. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2019; 175:443-449 10.1007/s10549-019-05162-7
• BRCA1 risk-reducing surgery appears to reduce risk of developing breast cancer Cite
  Irwin G, Hinds G, McFaul L, Morrison P, Harley I, McIntosh S. BRCA1 risk-reducing surgery appears to reduce risk of developing breast cancer. European Journal of Surgical Oncology. Elsevier BV; 2018; 44:S4 10.1016/j.ejso.2018.01.236
• Predictors of survival for breast cancer patients with a BRCA1 mutation Cite
  Narod SA, Huzarski T, Gronwald J, Byrski T, Marczyk E, Cybulski C, et al. Predictors of survival for breast cancer patients with a BRCA1 mutation. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2017; 168:513-521 10.1007/s10549-017-4605-x
• Racial disparities inBRCAtesting and cancer risk management across a population-based sample of young breast cancer survivors Cite
  Cragun D, Weidner A, Lewis C, Bonner D, Kim J, Vadaparampil ST, et al. Racial disparities inBRCAtesting and cancer risk management across a population-based sample of young breast cancer survivors. Cancer. Wiley; 2017; 123:2497-2505 10.1002/cncr.30621
• Bilateral Oophorectomy and Breast Cancer Risk inBRCA1andBRCA2Mutation Carriers Cite
  Kotsopoulos J, Huzarski T, Gronwald J, Singer CF, Moller P, Lynch HT, et al. Bilateral Oophorectomy and Breast Cancer Risk inBRCA1andBRCA2Mutation Carriers. JNCI: Journal of the National Cancer Institute. Oxford University Press (OUP); 2016; 109 10.1093/jnci/djw177
• Pathologic findings at risk-reducing salpingo-oophorectomy (RRSO) in germline BRCA mutation carriers with breast cancer: significance of bilateral RRSO at the optimal age in germline BRCA mutation carriers Cite
  Lee Y, Lee S, Kim K, Jung K, Lee J, Kim Y. Pathologic findings at risk-reducing salpingo-oophorectomy (RRSO) in germline BRCA mutation carriers with breast cancer: significance of bilateral RRSO at the optimal age in germline BRCA mutation carriers. Journal of Gynecologic Oncology. Asian Society of Gynecologic Oncology; Korean Society of Gynecologic Oncology and Colposcopy; 2017; 28 10.3802/jgo.2017.28.e3
• Associations of Premenopausal Hysterectomy and Oophorectomy With Breast Cancer Among Black and White Women: The Carolina Breast Cancer Study, 1993–2001 Cite
  Robinson WR, Nichols HB, Tse CK, Olshan AF, Troester MA. Associations of Premenopausal Hysterectomy and Oophorectomy With Breast Cancer Among Black and White Women: The Carolina Breast Cancer Study, 1993–2001. American Journal of Epidemiology. Oxford University Press (OUP); 2016; 184:388-399 10.1093/aje/kwv448
• Uterine Cancer After Risk-Reducing Salpingo-oophorectomy Without Hysterectomy in Women With BRCA Mutations Cite
  Shu CA, Pike MC, Jotwani AR, Friebel TM, Soslow RA, Levine DA, et al. Uterine Cancer After Risk-Reducing Salpingo-oophorectomy Without Hysterectomy in Women With BRCA Mutations. JAMA Oncology. American Medical Association (AMA); 2016; 2:1434 10.1001/jamaoncol.2016.1820
• Luteal versus follicular phase surgical oophorectomy plus tamoxifen in premenopausal women with metastatic hormone receptor-positive breast cancer Cite
  Love RR, Hossain SM, Hussain MM, Mostafa MG, Laudico AV, Siguan SSS, et al. Luteal versus follicular phase surgical oophorectomy plus tamoxifen in premenopausal women with metastatic hormone receptor-positive breast cancer. European Journal of Cancer. Elsevier BV; 2016; 60:107-116 10.1016/j.ejca.2016.03.011
• Breast Cancer Risk After Salpingo-Oophorectomy in Healthy BRCA1/2 Mutation Carriers: Revisiting the Evidence for Risk Reduction Cite
  Heemskerk-Gerritsen BAM, Seynaeve C, van Asperen CJ, Ausems MGEM, Collée JM, van Doorn HC, et al. Breast Cancer Risk After Salpingo-Oophorectomy in Healthy BRCA1/2 Mutation Carriers: Revisiting the Evidence for Risk Reduction. JNCI: Journal of the National Cancer Institute. Oxford University Press (OUP); 2015; 107 10.1093/jnci/djv033
• Family history and risk of breast cancer: nurses’ health study Cite
  Colditz GA, Kaphingst KA, Hankinson SE, Rosner B. Family history and risk of breast cancer: nurses’ health study. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2012; 133:1097-1104 10.1007/s10549-012-1985-9
• Oral contraceptives and risk of ovarian and breast cancers inBRCAmutation carriers: a meta-analysis Cite
  Cibula D, Zikan M, Dusek L, Majek O. Oral contraceptives and risk of ovarian and breast cancers inBRCAmutation carriers: a meta-analysis. Expert Review of Anticancer Therapy. Informa UK Limited; 2011; 11:1197-1207 10.1586/era.11.38
• N’oubliez pas les trompes ! Étude morphologique et immunohistochimique des trompes à risque génétique (mutation BRCA) Cite
  Chêne G, Raoelfils I, Cayre A, Dauplat J, Bignon Y, Jaffeux P, et al. N’oubliez pas les trompes ! Étude morphologique et immunohistochimique des trompes à risque génétique (mutation BRCA). Gynécologie Obstétrique & Fertilité. Elsevier BV; 2012; 40:14-18 10.1016/j.gyobfe.2011.07.043
• Breast Cancer Risk and Ovariectomy, Hysterectomy, and Tubal Sterilization in the Women's Contraceptive and Reproductive Experiences Study Cite
  Press DJ, Sullivan-Halley J, Ursin G, Deapen D, McDonald JA, Strom BL, et al. Breast Cancer Risk and Ovariectomy, Hysterectomy, and Tubal Sterilization in the Women's Contraceptive and Reproductive Experiences Study. American Journal of Epidemiology. Oxford University Press (OUP); 2010; 173:38-47 10.1093/aje/kwq339
• 500 Is risk-reducing mastectomy in BRCA1/2 mutation carriers with a history of unilateral breast cancer beneficial with respect to distant disease free survival and overall survival? Cite
  Heemskerk-Gerritsen B, Hooning M, Jager A, Tilanus-Linthorst M, Bartels C, van den Ouweland A, et al. 500 Is risk-reducing mastectomy in BRCA1/2 mutation carriers with a history of unilateral breast cancer beneficial with respect to distant disease free survival and overall survival?. European Journal of Cancer Supplements. Elsevier BV; 2010; 8:206 10.1016/s1359-6349(10)70521-8
• Penetrance of breast cancer, ovarian cancer and contralateral breast cancer in BRCA1 and BRCA2 families: high cancer incidence at older age Cite
  van der Kolk DM, de Bock GH, Leegte BK, Schaapveld M, Mourits MJE, de Vries J, et al. Penetrance of breast cancer, ovarian cancer and contralateral breast cancer in BRCA1 and BRCA2 families: high cancer incidence at older age. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2010; 124:643-651 10.1007/s10549-010-0805-3
• Breast Cancer Risk Factors Defined by Estrogen and Progesterone Receptor Status: The Multiethnic Cohort Study Cite
  Setiawan VW, Monroe KR, Wilkens LR, Kolonel LN, Pike MC, Henderson BE. Breast Cancer Risk Factors Defined by Estrogen and Progesterone Receptor Status: The Multiethnic Cohort Study. American Journal of Epidemiology. Oxford University Press (OUP); 2009; 169:1251-1259 10.1093/aje/kwp036
• Estrogenic action of commonly used fragrant agent citral induces prostatic hyperplasia Cite
  Geldof AA, Engel C, Rao BR. Estrogenic action of commonly used fragrant agent citral induces prostatic hyperplasia. Urological Research. Springer Science and Business Media LLC; 1992; 20:139-144 10.1007/bf00296526
• Pomegranate extract improves a depressive state and bone properties in menopausal syndrome model ovariectomized mice Cite
  Mori-Okamoto J, Otawara-Hamamoto Y, Yamato H, Yoshimura H. Pomegranate extract improves a depressive state and bone properties in menopausal syndrome model ovariectomized mice. Journal of Ethnopharmacology. Elsevier BV; 2004; 92:93-101 10.1016/j.jep.2004.02.006
• Milk Inhibits the Regression of 7,12-Dimethylbenz(a)anthracene-Induced Mammary Tumors in Ovariectomized Rats Cite
  Qin L, Xu J, Tezuka H, Wang P, Hoshi K. Milk Inhibits the Regression of 7,12-Dimethylbenz(a)anthracene-Induced Mammary Tumors in Ovariectomized Rats. Nutrition and Cancer. Informa UK Limited; 2008; 60:505-510 10.1080/01635580801927452